INTRODUCTION
In human T cells, Kv1.3 potassium channel plays an essential role in regulating the resting membrane potential and Ca 2+ signaling (1) (2) (3) . When the autoimmune disease-related CCR7 -effector memory T-cells are activated in the inflammation sites, expression of Kv1.3 channel in these cells significantly increases from approximately 250 channels to about 1500~2000 channels per cell. Such increased expression of Kv1.3 channel proteins does not occur in the naïve or central memory T cells homed in lymphoid organs (4, 5) . These findings suggest that selective suppression of effector memory T cells with specific Kv1.3 inhibitors could efficiently suppress immune responses to alleviate the diseases. Moreover, the therapeutic efficacy of Kv1.3 channel blocking was validated by in vitro assays and by in vivo animal models of T-cell mediated autoimmune diseases such as multiple sclerosis, type-1 diabetes, rheumatoid arthritis and psoriasis (1, 4, (6) (7) (8) . Progress in this area has promoted the extensive development of highly potent and selective Kv1.3 channel inhibitors, which may lead to a new class of drugs for autoimmune diseases.
Toxin peptides from natural venomous animals comprise the largest families of ion channel blockers, and they are becoming increasingly valuable sources of new drugs for channelopathies (9, 10) . With respect to the Kv1.3 channel, many structurally diverse peptide toxins, such as ChTX (11, 12) , ShK (13, 14) and OSK1 (15) , have been identified. Although these inhibitors can block potassium currents at the nM or pM concentrations, they lack sufficient specificity to distinguish between Kv1.3 and other related Kv1.x channels. Recently, chemical modifications and the deletion mutagenesis method have been used to improve the selectivity of these toxin peptides (16, 17) . For example, ShK-L5, derived from the sea anemone toxin ShK, exhibited a 100-fold selectivity for Kv1.3 (IC 50 = 69 pM) over Kv1.1 and more than 250-fold selectivity over all other tested channels (6) . A series of peptide analogs derived from the scorpion toxin OSK1 blocked Kv1.3 with improved selectivity through progressive deletions of N-and C-terminal sequences (15, 17) . Although the potency and selectivity of these peptide inhibitors are much better than those of small chemical molecules (18, 19) , the rational design of potent and selective blockers still remains a huge challenge.
Here we have rationally designed a highly specific Kv1.3 inhibitor peptide, named ADWX-1 (Autoimmune Drug from WenXin group) based on the scorpion toxin BmKTX (20) , using a structure-based strategy of manipulating three important residues. The new ADWX-1 peptide blocked Kv1.3 currents with picomolar affinity (IC 50 =1.89 pM), showing a 100-fold increase in inhibitory activity compared to native BmKTX peptide. Furthermore, ADWX-1 peptide displayed specificity on Kv1.3 over Kv1.1 and Kv1.2, for ~340-fold and >10
5 -fold, respectively. Moreover, the structure-function relationship of ADWX-1 peptide was characterized through alanine-scanning mutagenesis and computational modeling. Our work will facilitate the future structure-based design of specific peptide immunomodulators for the therapeutic target of Kv1.3 channels in T-cell mediated autoimmune diseases.
MATERIALS and METHODS

Site-directed Mutagenesis
ADWX-1 was generated by one overlapping PCR from BmKTX (21) . A second PCR reaction used the products of the overlapping PCR as templates. The primers used were: Sense primer 1, 5'-GTGAATTCGATGACGATGACAAG GTGGGTATTAATGTGAA-3'; Sense primer 2, 5'-GGTA TTAATGTGAAATGTAAGCATAGCCGC CAATGTCTGAAACCATGCAAGGATGC TG-3'; Antisense primer 1, 5'-GGTAC AATGGCATTTGCCATTGGTGCATTTA CCAAATCTCATTCCAGCATCCTTG-3'; Antisense primer 2, 5'-TAGCTCGAG TCACTTCGGGGTACAATGGCATTTGC-3'. The restriction enzyme sites are in bold, and an enterokinase cleavage site is underlined.
All ADWX-1 mutants were generated by overlapping PCR from ADWX-1, the PCR strategy used was the same as constructing ADWX-1.
Purification and Characterization of Toxin Peptides
The ADWX-1 and its mutant plasmids were digested with EcoRI and Xho I, and the cDNAs were subcloned into pGEX-6P-1. After transformed into E. coli Rosetta (DE3) cells, cells were cultured at 37 o C in LB medium with ampcillin (100 μg/mL). When cell density reached OD=0. Electrophysiological experiments were carried out at 22~25°C using the patch-clamp whole-cell recording mode. Cells were bathed with mammalian Ringer's solution: 5 mM KCl, 140 mM NaCl, 10 mM HEPES, 2 mM CaCl 2 , 1 mM MgCl 2 , 10 mM D-Glucose, pH 7.4 with NaOH. When ADWX-1 and the mutant toxin peptides were applied, 0.01% BSA was added to the Ringer's solution. A multichannel micro perfusion system MPS-2 (INBIO Inc, Wuhan, China) was used to exchange the external recording bath solution. The pipette solution contained: 140 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM Na 2 ATP, 5 mM HEPES (pH 7.4 with NaOH). All channel currents were elicited by depolarizing voltage steps of 200 ms from the holding potential -80 mV to +50 mV. Membrane currents were measured with an EPC 10 patch clamp amplifier (HEKA Elekt-ronik, Lambrecht, Germany) interfaced to a computer running acquisition and analysis software (Pulse).
Data analyses were performed with IgorPro (WaveMetrics, Lake Oswego, OR), and IC 50 values were deduced by fitting a modified Hill equation to the data: I toxin /I control =1/1+([toxin peptide]/IC 50 ), where I is the peak current to the normalized data points obtained with at least four different toxin peptide concentrations. Results are mostly shown as mean ± S.E, n being the number of experiments.
Molecular Modeling and Docking
The structures of mKv1.3 and ADWX-1 were modeled using KcsA (PDB code: 1BL8) and BmKTX (PDB code:
as templates through the SWISSMODEL server (22) . Using the modeled ADWX-1 and Kv1.3 structures, ZDOCK (23) program was used to generate the models for the ADWX-1-Kv1.3 complex. Several conformations of ADWX-1 modeled from BmKTX were used to improve the rigid performance of ZDOCK. Each docking group gives 2,000 predicted complex structures. Through clustering analysis with the mutagenesis results, some possible hits were screened out, followed by a 500-steps energy minimization and a 500 ps unrestrained molecular dynamics performed on each possible toxin peptide-channel complex using the SANDER module in the AMBER 8 suit programs (24) .
Molecular Dynamic Simulations and Calculation of Binding Free Energies by MM-PBSA
All MD simulations were performed by using the Amber 8 program on a 32-CPU Dawning TC4000L cluster (Beijing, China). The final ADWX-1-Kv1.3 complex structure was sufficiently equilibrated by 7 ns unrestrained molecular dynamic simulations to introduce enough flexibility for both the channel and the toxin peptide. Temperature was set at 300 K with the cutoff distance of 12 Å used for unbounded interaction. The ff99 force field (Parm99) (25) was applied throughout the energy minimization and MD simulations. Before the unrestrained MD simulation was performed, we also employed enough equilibration steps for 400 ps from a larger force constant 5.0 (kcal/mol)/Å macromolecular simulations (26, 27) was used instead of explicit water.
The MM-PBSA module of AMBER 8 was used to calculate the binding free energies for ADWX-1 binding to Kv1.3 (24, 28) . This MM-PBSA module also contains a computational alanine scanning approach for evaluating the importance of residues functioning in protein-protein interactions. This program was employed for identifying the most reasonable candidate complexes. The detailed method of calculating binding free energies between inhibitory peptides and potassium channels was previously described (29, 30) .
RESULTS
Design strategy of a potent Kv1.3 channel inhibitor
Native BmKTX toxin peptide is a potent Kv1.3 blocker with a K d value of 0.2 nM (20,21), therefore, was selected as a template for designing a new analog with higher potency in this work. In order to obtain more potent BmKTX peptide analogs, we adopted the following strategies. First, we adjusted the distribution of negatively charged residues in BmKTX peptide. In the BmKTX structure (PDB code: 1BKT), there is ~5 Å between the two Cα atoms from Asp 33 and Lys 26 residues (Fig. 1B) . Such close distance impedes the side chain of the conserved Lys 26 to block channel pore due to the strong electrostatic repulsion between Asp 33 and the conserved aspartic acid in the S6-filter linker (Fig. 1B) . In this work, Asp 33 was substituted by a conserved histidine residue among α-KTx3 scorpion toxins (31) (Fig. 1A-C) ; Second, we strengthened the polar interaction between polar residues from the peptide and Kv1.3. The side chain of Lys 26 is expected to insert into the channel pore. We replaced the adjacent hydrophobic Ile 28 of BmKTX with the polar threonine residue for a more favorable interaction (Fig. 1A-C) . Third, we introduced a positively charged residue in the beginning of the α helix domain. There are four negatively charged residues in the turret of Kv1.3, Arg 11 was introduced for a potential salt-bridge interaction between K1.3 and the toxin peptide (Fig. 1C) . With these three changes to improve the potency of BmKTX, a new ADWX-1 peptide was rationally designed (Fig. 1A) .
Pharmacological activities of ADWX-1 peptide on Kv channels
To experimentally test the ADWX-1 peptide, we have characterized the pharmacological activity of ADWX-1 on Kv1.3 channels. Recombinant ADWX-1 peptide was purified from E. coli. Fig. 2A showed a peptide of 4 kDa cleaved by enterokinase from the 30 kDa fusion protein.
The mixture of ADWX-1 peptide and GST protein was completely separated by reversed-phase HPLC (Fig. 2B) . The peak at 12-13 min corresponding to ADWX-1 peptide was collected and subsequently identified by mass spectrometry analysis (Fig. 2C) . The molecular weight of ADWX-1 was 4072.8 Da, which is close to the calculated molecular mass of 4071.1 Da.
Next we investigated the effect of recombinant ADWX-1 peptide on Kv1.3 channel together with Kv1.1 and Kv1.2 channels. All channels were expressed in the transiently transfected HEK293 cells. Fig.  3A and 3B show the effects of ADWX-1 peptide on Kv1.3 and Kv1.1 currents elicited by 200-ms depolarizing pulses from a holding potential of -80 to 50 mV. As shown in Fig. 3A , ADWX-1 had a very high potency towards Kv1.3 channels with IC 50 of 1.89 ± 0.53 pM, showing a ~100-fold increase in binding affinity compared with that of BmKTX (20, 21) . In addition, ADWX-1 also exhibited over 340-fold selectivity for Kv1.3 over Kv1.1 (IC 50 =0.65 ± 0.25 nM) (Fig. 3B and C) . Furthermore, 100 nM ADWX-1 peptide only blocked about 10% of the peak current of Kv1.2 channels (Fig. 3C and data not shown) . These data showed that the designed ADWX-1 peptide was the most selective and potent peptide inhibitor among identified Kv1.3-specific inhibitors, such as AgTX2 (32), ShK-L5 (6), AOSK1 and [△ [36] [37] [38] ]-AOSK1 (17) .
Functional sites of ADWX-1 identified by alanine-scanning mutagenesis
To identify the functional sites of ADWX-1 involved in the interaction with Kv1.3 channels, eight residues were individually mutated to alanine, based on the model of the ADWX-1 peptide-Kv1.3 channel complex. Compared with the ADWX-1 peptide, the CD spectra of eight mutants showed no significant changes in the secondary structure (Fig. 4) , indicating that ADWX-1 and its mutant peptides all adopted the same overall structural topology. Furthermore, we also expressed and purified recombinant BmKTX, whose CD spectrum was measured and compared with that of ADWX-1 (Fig. 4A) . Although three residues of BmKTX were changed, the structure of the resulted ADWX-1 peptide was almost the same as that of BmKTX peptide.
The blocking activities of these ADWX-1 mutant peptides were then tested on Kv1.3 channels. Fig. 5 A-H showed the representative current traces before and after treatments with mutant peptides. Table 1 listed the average IC 50 values for these mutants. As illustrated in Table 1 Given the characterized functional residues of ADWX-1, a reasonable model of the ADWX-1-Kv1.3 complex was obtained to reveal the recognition mechanism of ADWX-1 peptide toward Kv1.3 channels through combined computational approaches (29, 30) . First, the structures of the ADWX-1 peptide and the Kv1.3 channel were respectively modeled based on the structural similarity with their templates. Second, molecular docking was performed on the modeled ADWX-1 and Kv1.3 proteins using the ZDOCK program (23). The docking results were then filtered by scoring combined with detailed mutagenesis information and interaction energy analysis. Third, to introduce flexibility for the rigid docking results, an energy minimization followed by 500 ps molecular dynamics (MD) simulation was performed on each selected complex to better discriminate among them. Finally, an ADWX-1-Kv1.3 complex structural model was screened out using the computational alanine-scanning method in MM-PBSA (24, 28) , which was compared with the experimental alanine-scanning mutagenesis results. An additional 7 ns unrestrained MD simulation was performed to sufficiently equilibrate this model. Fig. 6A indicated that both the peptide and the channel were pre-aligned and induced to fit in their nanosecond-scale diffusional encounter, and then led to a specifically stable complex. An overall high degree of correlation was found between the calculation and the experiments on mutational effects (Fig. 6B and C) . In (Fig. 6D and Fig.7A) , and gave the biggest G △△ binding value of 5.11 kcal/mol among all mutants. The conserved pore-blocking Lys 26 residue was found to plug its side chain into channel selectivity filter during the whole simulation as predicted ( Fig. 6D and Fig.7A ), and the G △△ binding value of 3.58 kcal/mol correlated well with the mutation effect. Furthermore, the Phe (Fig. 7D) .
The binding affinity of ADWX-1 to Kv1.3 was affected little by the Thr 35 mutation, which was in accord with the observation that this residue located away from the interface. Hence, the model of the complex well elucidated the molecular basis of the major determinants for the high affinity of ADWX-1 binding to Kv1.3 channels.
DISCUSSION
In the current study, we have designed the ADWX-1 peptide, an analog of the scorpion toxin BmKTX. ADWX-1 exhibited high potency and selectivity towards Kv1.3 channels. This design was based on many factors affecting the toxin peptide-potassium channel interactions, such as the distribution of peptide functional residues, residue polarity, and especially the negatively charged residues in toxin peptides. There is a strong electrostatic repulsion between the negatively charged Asp 33 in the toxin peptide and the conserved aspartic acid in the S6-filter linker of Kv channels (Fig. 1B) . The side chain of the conserved Lys 26 residue is likely unable to insert into the channel selectivity filter. Thus, the pharmacological activities and profile of toxin peptides could be altered through changing the distribution of negatively charged residues together with modifying the possible contact residues with the structure-guided approach. We addressed the above issues by producing a new ADWX-1 peptide, through mutating Asp 33 , Gly 11 Natural venoms provide many candidate peptides for designing potential drug leads targeting the Kv1.3 channels. However, present strategies for improving the selectivity and activity of these candidate peptides still remain a significant challenge. Our success with the design of ADWX-1 suggests that rational design based on the model of the peptide-channel complex will accelerate the development of diagnostic and therapeutic agents using venom peptides as scaffolds. Table. 1. Each value represents mean ± S.E. n, the number of separate experiments.
